Saleem Ayesha, Padakanti Suraj S, Hajjaj Mohsin, Akram Muhammad Shariq, Siddenthi Sowmya Manjari, Kumari Versha, Gandhi Fenil, Sakhamuri Lakshmi Tejaswi, Belletieri Christopher, Erravelli Pavan K, Usama Ali
Internal Medicine, Jinnah Hospital Lahore, Lahore, PAK.
Internal Medicine, Ramaiah Medical College, Bangalore, IND.
Cureus. 2025 Jul 6;17(7):e87378. doi: 10.7759/cureus.87378. eCollection 2025 Jul.
Vitamin D supplementation may have beneficial effects on cardiovascular outcomes in patients with chronic kidney disease (CKD), but the underlying data are conflicting. We conducted a meta-analysis to investigate the effect of vitamin D on cardiovascular outcomes in patients with CKD. We searched MEDLINE (via PubMed), the Cochrane Library, Scopus, and ClinicalTrials.gov from inception to 16 March 2024 for all randomized controlled trials (RCTs) assessing vitamin D supplementation in patients with CKD and reporting cardiovascular outcomes. Our primary outcomes were the incidence of adverse cardiovascular events and the change in left ventricular ejection fraction (LVEF) and left ventricular mass index (LVMI). Our secondary outcomes were the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Data were pooled using risk ratio (RR) and mean difference as the effect measures. A total of 11 RCTs were included in our review. Vitamin D supplementation reduced the risk of adverse cardiovascular events in patients with CKD (RR 0.39; 95% CI 0.22 to 0.69; I2=0). There was no significant difference in LVEF, LVMI, SBP, and DBP between the vitamin D and control groups. Vitamin D supplementation does not affect adverse cardiovascular events, LVEF, LVMI, SBP, and DBP. Further large-scale RCTs and mechanistic studies are needed to understand the potential benefits of vitamin D supplementation in this patient population.
补充维生素D可能对慢性肾脏病（CKD）患者的心血管结局产生有益影响，但相关基础数据存在矛盾。我们进行了一项荟萃分析，以研究维生素D对CKD患者心血管结局的影响。我们检索了MEDLINE（通过PubMed）、Cochrane图书馆、Scopus和ClinicalTrials.gov，从数据库建立至2024年3月16日，查找所有评估CKD患者补充维生素D并报告心血管结局的随机对照试验（RCT）。我们的主要结局是不良心血管事件的发生率以及左心室射血分数（LVEF）和左心室质量指数（LVMI）的变化。次要结局是收缩压（SBP）和舒张压（DBP）的变化。使用风险比（RR）和均值差作为效应量合并数据。我们的综述共纳入11项RCT。补充维生素D降低了CKD患者发生不良心血管事件的风险（RR 0.39；95%CI 0.22至0.69；I²=0）。维生素D组与对照组在LVEF、LVMI、SBP和DBP方面无显著差异。补充维生素D不会影响不良心血管事件、LVEF、LVMI、SBP和DBP。需要进一步开展大规模RCT和机制研究，以了解补充维生素D对该患者群体的潜在益处。
